Open Access. Powered by Scholars. Published by Universities.®
Virginia Commonwealth University
Internal Medicine Publications
BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; KERATINOCYTE GROWTH-FACTOR; TOTAL-BODY IRRADIATION; NON-HODGKINS-LYMPHOMA; HIGH-DOSE ETOPOSIDE; PREPARATORY REGIMEN; DOUBLE-BLIND; CHEMOTHERAPY; PROPHYLAXIS
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Palifermin For Oral Mucositis After Intensive Therapy For Hematologic Cancers, Ricardo Spielberger, Patrick Stiff, William Bensinger, Teresa Gentile, Daniel Weisdorf, Tarun Kewalramani, Thomas Shea, Saul Yanovich, Keith Hansen, Stephen Noga, John Mccarty, C. Frederick Lemaistre, Eric C. Sung, Bruce R. Blazar, Dieter Elhardt, Mon-Gy Chen, Christos Emmanouilides
Palifermin For Oral Mucositis After Intensive Therapy For Hematologic Cancers, Ricardo Spielberger, Patrick Stiff, William Bensinger, Teresa Gentile, Daniel Weisdorf, Tarun Kewalramani, Thomas Shea, Saul Yanovich, Keith Hansen, Stephen Noga, John Mccarty, C. Frederick Lemaistre, Eric C. Sung, Bruce R. Blazar, Dieter Elhardt, Mon-Gy Chen, Christos Emmanouilides
Internal Medicine Publications
BACKGROUND: Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effective treatment. We tested the ability of palifermin (recombinant human keratinocyte growth factor) to decrease oral mucosal injury induced by cytotoxic therapy. METHODS: This double-blind study compared the effect of palifermin with that of a placebo on the development of oral mucositis in 212 patients with hematologic cancers; 106 patients received palifermin (60 microg per kilogram of body weight per day) and 106 received a placebo intravenously for three consecutive days immediately before the initiation of conditioning therapy (fractionated total-body irradiation plus high-dose chemotherapy) and after autologous …